Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan
Cardiovasc Res. 2016 Jan 1;109(1):162-73. doi: 10.1093/cvr/cvv248. Epub 2015 Nov 3.
The progression of pathological left ventricular remodelling leads to cardiac dysfunction and contributes to the occurrence of malignant arrhythmias and sudden cardiac death. The underlying molecular mechanisms remain unclear, however. Our aim was to examine the role of the renin-angiotensin system (RAS) in the mechanism underlying arrhythmogenic cardiac remodelling using a transgenic mouse expressing a cardiac-specific dominant-negative form of neuron-restrictive silencer factor (dnNRSF-Tg). This mouse model exhibits progressive cardiac dysfunction leading to lethal arrhythmias.
Subcutaneous administration of aliskiren, a direct renin inhibitor, significantly suppressed the progression of pathological cardiac remodelling and improved survival among dnNRSF-Tg mice while reducing arrhythmogenicity. Genetic deletion of the angiotensin type 1a receptor (AT1aR) similarly suppressed cardiac remodelling and sudden death. In optical mapping analyses, spontaneous ventricular tachycardia (VT) and fibrillation (VF) initiated by breakthrough-type excitations originating from focal activation sites and maintained by functional re-entry were observed in dnNRSF-Tg hearts. Under constant pacing, dnNRSF-Tg hearts exhibited markedly slowed conduction velocity, which likely contributes to the arrhythmogenic substrate. Aliskiren treatment increased conduction velocity and reduced the incidence of sustained VT. These effects were associated with suppression of cardiac fibrosis and restoration of connexin 43 expression in dnNRSF-Tg ventricles.
Renin inhibition or genetic deletion of AT1aR suppresses pathological cardiac remodelling that leads to the generation of substrates maintaining VT/VF and reduces the occurrence of sudden death in dnNRSF-Tg mice. These findings demonstrate the significant contribution of RAS activation to the progression of arrhythmogenic substrates.
病理性左心室重构的进展导致心脏功能障碍,并促成恶性心律失常和心脏性猝死的发生。然而,其潜在的分子机制尚不清楚。我们的目的是使用表达心脏特异性显性负形式的神经元限制性沉默因子(dnNRSF-Tg)的转基因小鼠来研究肾素-血管紧张素系统(RAS)在致心律失常性心脏重构机制中的作用。该小鼠模型表现出进行性心脏功能障碍,导致致命性心律失常。
皮下给予直接肾素抑制剂阿利克仑可显著抑制 dnNRSF-Tg 小鼠病理性心脏重构的进展并提高其生存率,同时降低心律失常性。血管紧张素 1 型受体(AT1aR)的基因缺失也可抑制心脏重构和猝死。在光学标测分析中,在 dnNRSF-Tg 心脏中观察到源自局灶性激活部位的突破性兴奋引发的自发性室性心动过速(VT)和颤动(VF)。在持续起搏下,dnNRSF-Tg 心脏表现出明显减慢的传导速度,这可能是致心律失常的基础。阿利克仑治疗可增加传导速度并降低持续 VT 的发生率。这些作用与心脏纤维化的抑制和 dnNRSF-Tg 心室中连接蛋白 43 表达的恢复有关。
肾素抑制或 AT1aR 的基因缺失可抑制病理性心脏重构,从而产生维持 VT/VF 的基质,并减少 dnNRSF-Tg 小鼠猝死的发生。这些发现表明 RAS 激活对致心律失常基质进展的重要贡献。